| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 500mg | |||
| 1g | |||
| Other Sizes |
| Targets |
WAY-278705 targets phosphoinositide 3-kinase (PI3K). PI3K is a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, survival, and intracellular trafficking. WAY-278705 functions as a modulator of PI3K activity. It is specifically annotated as a PI3K modulator across multiple reputable chemical biology databases. The compound's interaction with PI3K makes it a valuable tool for studying the role of this kinase in various signaling pathways.
|
|---|---|
| ln Vitro |
Specific in vitro potency values such as IC50 for WAY-278705 have not been extensively reported in the available literature. It is characterized as a PI3K modulator. Further studies would be required to characterize its specific inhibitory activity and selectivity against PI3K isoforms.
|
| ln Vivo |
Specific in vivo activity data for WAY-278705 are not extensively reported. As a PI3K modulator, it would be expected to influence PI3K-dependent signaling pathways in vivo. Further studies would be required to evaluate its efficacy in animal models of cancer or other PI3K-driven diseases.
|
| Enzyme Assay |
PI3K activity is measured using in vitro kinase assays with recombinant PI3K enzyme. The enzyme is incubated with ATP and a lipid substrate (phosphatidylinositol) in the presence of WAY-278705 at varying concentrations. Phosphorylation is measured using radioactive or fluorescence-based detection methods, and IC50 values are calculated from dose-response curves.
|
| Cell Assay |
The cellular activity of WAY-278705 is evaluated in PI3K-dependent cell lines. Cells are treated with the compound, and downstream signaling (e.g., AKT phosphorylation at Ser473 and Thr308) is assessed by Western blot. Cell viability and proliferation are measured using MTT or CellTiter-Glo assays to assess functional effects.
|
| Animal Protocol |
In vivo efficacy of WAY-278705 would typically be evaluated in mouse models of cancer or other PI3K-driven diseases. Animals would be administered the compound, and tumor growth or disease progression would be assessed. Pharmacodynamic endpoints would include assessment of PI3K pathway inhibition in tumor tissues.
|
| ADME/Pharmacokinetics |
WAY-278705 has a molecular formula of C14H15BrN2OS and a molecular weight of 339.25 g/mol. Its chemical name is N-(6-bromobenzo[d]thiazol-2-yl)cyclohexanecarboxamide. The compound is soluble in DMSO (10 mM). For storage, the powder can be kept at -20°C for up to 3 years or at 4°C for up to 2 years; in solvent, it can be stored at -80°C for 6 months or at -20°C for 1 month.
|
| Toxicity/Toxicokinetics |
Comprehensive toxicological data for WAY-278705 are limited. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| Additional Infomation |
WAY-278705 is a PI3K modulator used for research on PI3K signaling pathways. It has garnered attention for potential biological activities, particularly in anticancer and antimicrobial research. The compound is a valuable tool for studying the role of PI3K in cellular signaling and disease. It is available from multiple reputable vendors.
|
| Molecular Formula |
C14H15BRN2OS
|
|---|---|
| Molecular Weight |
339.25
|
| Exact Mass |
338.008
|
| Elemental Analysis |
C, 49.57; H, 4.46; Br, 23.55; N, 8.26; O, 4.72; S, 9.45
|
| CAS # |
476280-90-7
|
| PubChem CID |
4604615
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.6±0.1 g/cm3
|
| Index of Refraction |
1.691
|
| LogP |
4.67
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
19
|
| Complexity |
335
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
BrC1C=CC2=C(C=1)SC(=N2)NC(C1CCCCC1)=O
|
| InChi Key |
KYWBPMHOAGNHSB-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H15BrN2OS/c15-10-6-7-11-12(8-10)19-14(16-11)17-13(18)9-4-2-1-3-5-9/h6-9H,1-5H2,(H,16,17,18)
|
| Chemical Name |
N-(6-bromo-1,3-benzothiazol-2-yl)cyclohexanecarboxamide
|
| Synonyms |
WAY-278705; WAY278705; WAY 278705
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9477 mL | 14.7384 mL | 29.4768 mL | |
| 5 mM | 0.5895 mL | 2.9477 mL | 5.8954 mL | |
| 10 mM | 0.2948 mL | 1.4738 mL | 2.9477 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
